SEC Form 4 · accession 0001104659-16-121557
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shawn Lynch
Officer — Chief Financial Officer
Period of report
May 16, 2016
Accepted (ET)
May 17, 2016 · 11:31 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $8.88 | May 16, 2016 | A | 146,600 | A | — | May 16, 2026 | Common Stock | 146,600 | 146,600 | D |
Explanation of responses
- F125% of the total shares vest on 05/16/2017, and the remaining shares vest in substantially equal monthly installments over the following 36 months, to be fully vested on 05/16/2020.